Daily pill looming for GLP-1 receptor agonists? Eli Lilly drafting TGA application
Some patients with diabetes did not want injectable therapies, said Dr Gary Deed.
Eli Lilly is preparing a TGA application for an oral GLP-1 receptor agonist to treat early diabetes following publication of phase III trial results.
The once-daily pill orforglipron reduced both average HbA1c levels and body weight after 40 weeks, according to the study published in the New England Journal of Medicine.
It involved 559 adults with type 2 diabetes who had not used any diabetes medicine in the previous three months and had never used insulin therapy.
All had a baseline HbA1c between 7.0% and 9.5% and a BMI of at least 23kg/m².
